Calidi Biotherapeutics Quote - CLDI

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.06

Bid

Offer

Volume

31,214

1.0016 Day's Range 1.10

0.96 52 Week Range 31.60

Market Cap

10.477M

Previous Close

1.0312

Open

1.01

Last Trade

105

1.06

Last Trade Time

Financial Volume

US$ 33,048

VWAP

1.0587

Average Volume (3m)

178,415

Shares Outstanding

9,884,153

Dividend Yield

PE Ratio

-0.37

Earnings Per Share (EPS)

-2.96

Revenue

Net Profit

-29.22M

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.calidibio.com

Headquarters

Wilmington, Delaware, USA

Founded

Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was US$1.03. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of US$ 0.96 to US$ 31.60.

Calidi Biotherapeutics currently has 9,884,153 shares in issue. The market capitalisation of Calidi Biotherapeutics is US$10.19 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.37.

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the...

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi to Effect Reverse Stock Split

Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage...

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the...

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to...

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued...

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400...

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.02	-1.85185185185	1.08	1.103	0.96	48394	1.04341884	CS
4	-0.15	-12.3966942149	1.21	1.23	0.96	61292	1.12039896	CS
12	-0.74	-41.1111111111	1.8	1.95	0.96	178415	1.48999543	CS
26	-4.781	-81.8524225304	5.841	7.4	0.96	1102245	2.13042381	CS
52	-29.54	-96.5359477124	30.6	31.6	0.96	663110	3.3928085	CS
156	-44.04	-97.6496674058	45.1	50	0.96	619104	3.66393549	CS
260	-44.04	-97.6496674058	45.1	50	0.96	619104	3.66393549	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 61.24 (30.94%)	5.16M
PLAGPlanet Green Holdings Corp	US$ 2.07 (25.50%)	75.47k
WYYWidePoint Corporation	US$ 3.98 (17.54%)	227.28k
SLIStandard Lithium Ltd	US$ 2.40 (14.29%)	5.2M
PWPower REIT	US$ 1.3505 (12.54%)	11.15M
SCHGSchwab US Large Cap Growth	US$ 26.405 (-74.94%)	3.29M
SCHXSchwab US Large Cap	US$ 22.875 (-66.44%)	3.18M
SCHBSchwab US Broad Market	US$ 22.39 (-66.43%)	1.25M
FNDBSchwab Fundamental US Broad Market ETF	US$ 23.591 (-66.36%)	83.78k
FNDXSchwab Fundamental US Large Company ETF	US$ 24.07 (-66.35%)	861.54k
YANGDirexion Daily FTSE China Bear 3X Shares New	US$ 3.187 (-1.64%)	93.9M
FXIiShares China Large Cap	US$ 33.45 (0.69%)	69.11M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 38.67 (2.22%)	58.43M
XLFFinancial Select Sector	US$ 46.51 (1.93%)	51.9M
SOXSDirexion Daily Semiconductor Bear 3X Shares New	US$ 18.96 (-2.27%)	47.86M